HUE052128T2 - Eljárás az 1-(5,6-diklór-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-karbonsav meglumin sója kristályainak elõállítására - Google Patents

Eljárás az 1-(5,6-diklór-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-karbonsav meglumin sója kristályainak elõállítására

Info

Publication number
HUE052128T2
HUE052128T2 HUE18191088A HUE18191088A HUE052128T2 HU E052128 T2 HUE052128 T2 HU E052128T2 HU E18191088 A HUE18191088 A HU E18191088A HU E18191088 A HUE18191088 A HU E18191088A HU E052128 T2 HUE052128 T2 HU E052128T2
Authority
HU
Hungary
Prior art keywords
imidazol
pyrazole
benzo
dichloro
carboxylic acid
Prior art date
Application number
HUE18191088A
Other languages
English (en)
Inventor
Kia Sepassi
Michele C Rizzolio
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HUE052128T2 publication Critical patent/HUE052128T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
HUE18191088A 2011-10-25 2012-10-25 Eljárás az 1-(5,6-diklór-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-karbonsav meglumin sója kristályainak elõállítására HUE052128T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161551395P 2011-10-25 2011-10-25

Publications (1)

Publication Number Publication Date
HUE052128T2 true HUE052128T2 (hu) 2021-04-28

Family

ID=47116519

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18191088A HUE052128T2 (hu) 2011-10-25 2012-10-25 Eljárás az 1-(5,6-diklór-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-karbonsav meglumin sója kristályainak elõállítására

Country Status (15)

Country Link
US (4) US9273034B2 (hu)
EP (3) EP3461820B1 (hu)
JP (2) JP6122862B2 (hu)
KR (1) KR102087020B1 (hu)
CN (2) CN104053439B (hu)
AU (2) AU2012328763A1 (hu)
BR (1) BR112014009910B1 (hu)
CA (1) CA2853455C (hu)
CY (1) CY1123426T1 (hu)
ES (3) ES2574262T3 (hu)
HK (1) HK1202237A1 (hu)
HU (1) HUE052128T2 (hu)
IN (1) IN2014DN03155A (hu)
MX (2) MX368157B (hu)
WO (1) WO2013063221A1 (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2294066E (pt) 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
AU2012308238B2 (en) 2011-09-14 2017-05-25 Neupharma, Inc. Certain chemical entities, compositions, and methods
EP3461820B1 (en) * 2011-10-25 2020-07-29 Janssen Pharmaceutica NV Method for obtaining crystals of meglumine salt of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
EP2806874B1 (en) 2012-01-25 2017-11-15 Neupharma, Inc. Quinoxaline-oxy-phenyl derivatives as kinase inhibitors
CN104812389B (zh) 2012-09-24 2020-07-17 润新生物公司 某些化学实体、组合物及方法
US9725421B2 (en) 2012-11-12 2017-08-08 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
CN104610153B (zh) * 2015-01-19 2017-02-22 沈阳中海生物技术开发有限公司 奥扎格雷葡甲胺盐及其组合物、制备方法和用途
AU2019319448B2 (en) 2018-08-07 2022-06-02 Metagone Biotech Inc. Ammonium salts of 3-(3,5-dibromo-4-hydroxybenzyliden)-5-indo-1,3-dihydroindol-2-one and uses thereof
JPWO2021107110A1 (hu) 2019-11-28 2021-06-03
US20230218592A1 (en) 2020-04-20 2023-07-13 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
TW202313072A (zh) 2021-05-27 2023-04-01 美商凱立克斯生物製藥股份有限公司 檸檬酸鐵之兒科調配物

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1207994B (it) * 1986-01-03 1989-06-01 Therapicon Srl Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche.
ATE83381T1 (de) 1986-10-22 1993-01-15 Schering Corp Verwendung von rekombiniertem menschlichem alpha- interferon zur herstellung eines arzneimittels zur behandlung des aids-virus.
DE3824658A1 (de) 1988-07-15 1990-01-18 Schering Ag N-hetaryl-imidazolderivate
US5258362A (en) 1991-06-11 1993-11-02 Abbott Laboratories Renin inhibiting compounds
EP0650960B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
EP0832065B1 (en) 1995-06-06 2001-10-10 Pfizer Inc. Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
DK0970095T3 (da) 1997-03-07 2004-03-08 Metabasis Therapeutics Inc Hidtil ukendte benzimidazolinhibitorer for fructose-1,6-bisphosphase
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
BR9908332A (pt) 1998-02-27 2000-11-07 Pfizer Prod Inc Derivados de n-[carbonil(anel di ou triaza diinsaturado de cinco membros substituìdo)] derivados de guanidina para tratamento de esquemia
ATE287237T1 (de) 1999-11-22 2005-02-15 Mallinckrodt Inc Pulsoximetersensor mit einem breiteren metallband
GB9929037D0 (en) 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
DK1644336T3 (da) 2003-06-06 2011-05-09 Fibrogen Inc Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin
ES2311858T3 (es) 2003-07-28 2009-02-16 Janssen Pharmaceutica Nv Derivados de benzimidazol, benzotiazol y benzoxazol y su uso como moduladores de lta4h.
RU2329261C2 (ru) 2003-12-29 2008-07-20 Баниу Фармасьютикал Ко., Лтд. Новое 2-гетероарил-замещенное производное бензимидазола
WO2006094292A2 (en) 2005-03-02 2006-09-08 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
CA2610956A1 (en) 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
EP1960363B1 (en) 2005-12-09 2014-01-22 Amgen, Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions and uses thereof
CA2640435C (en) 2006-01-27 2011-11-01 Fibrogen, Inc. Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
PE20071020A1 (es) 2006-03-07 2007-12-11 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa
US20090176825A1 (en) 2006-05-16 2009-07-09 Fitch Duke M Prolyl hydroxylase inhibitors
AR061570A1 (es) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto
JP5113838B2 (ja) 2006-06-26 2013-01-09 アケビア セラピューティックス, インコーポレイテッド プロリルヒドロキシラーゼ阻害剤および使用方法
WO2008033739A2 (en) 2006-09-12 2008-03-20 Neurogen Corporation Benzimidazole carboxamide derivatives
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
DE102006050513A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substitiuierte Dihydropyrazolone und ihre Verwendung
JP5178738B2 (ja) 2006-12-20 2013-04-10 メルク・シャープ・アンド・ドーム・コーポレーション 新規なjnk阻害剤
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
WO2008130527A1 (en) 2007-04-18 2008-10-30 Merck & Co., Inc. Novel 1,8-naphthyridine compounds
ES2442847T3 (es) 2007-04-18 2014-02-13 Amgen, Inc Quinolonas y azaquinolonas que inhiben la prolil hidroxilasa
WO2008137084A2 (en) 2007-05-04 2008-11-13 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
CA2685216C (en) 2007-05-04 2014-07-08 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
BRPI0721950A2 (pt) * 2007-08-22 2015-09-29 4Sc Ag indolopiridinas como inibidores da proteína de fuso de cinesina
DE102007048447A1 (de) 2007-10-10 2009-04-16 Bayer Healthcare Ag Substituierte Dihydropyrazolthione und ihre Verwendung
DE102007049157A1 (de) 2007-10-13 2009-04-16 Bayer Healthcare Ag Substituierte Dihydrotriazolone und ihre Verwendung
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
US20100298324A1 (en) 2007-12-19 2010-11-25 Smith Kline Beecham Corporation Prolyl Hydroxylase Inhibitors
WO2009086592A1 (en) 2008-01-04 2009-07-16 Garvan Institute Of Medical Research Method of increasing metabolism
WO2009089547A1 (en) 2008-01-11 2009-07-16 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
AU2009217543A1 (en) 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Tetrahydro-1H-pyrrolo fused pyridones
AU2009217540B2 (en) 2008-02-25 2013-10-10 Merck Sharp & Dohme Corp. Tetrahydrofuropyridones
CN101951775A (zh) 2008-02-25 2011-01-19 默沙东公司 四氢噻吩并吡啶
JP5557832B2 (ja) 2008-03-18 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 置換4−ヒドロキシピリジン−5−カルボキサミド
PT2294066E (pt) * 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
JP5643233B2 (ja) 2009-02-10 2014-12-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap プロリルヒドロキシラーゼ阻害物質としてのキナゾリノン
US8796263B2 (en) 2010-08-13 2014-08-05 Janssen Pharmaceutica Nv 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors
EP3461820B1 (en) * 2011-10-25 2020-07-29 Janssen Pharmaceutica NV Method for obtaining crystals of meglumine salt of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid

Also Published As

Publication number Publication date
CN106038556A (zh) 2016-10-26
JP6122862B2 (ja) 2017-04-26
BR112014009910B1 (pt) 2020-06-30
US9708298B2 (en) 2017-07-18
EP3091009B1 (en) 2018-08-29
HK1202237A1 (zh) 2015-09-25
NZ624022A (en) 2015-05-29
AU2017204598A1 (en) 2017-07-27
JP2017141270A (ja) 2017-08-17
US20140329873A1 (en) 2014-11-06
EP3461820A1 (en) 2019-04-03
KR20140094547A (ko) 2014-07-30
US9273034B2 (en) 2016-03-01
AU2017204598B2 (en) 2019-03-28
MX344109B (es) 2016-12-05
MX2014005075A (es) 2014-08-08
WO2013063221A1 (en) 2013-05-02
US10807969B2 (en) 2020-10-20
AU2012328763A1 (en) 2014-05-01
EP3091009A1 (en) 2016-11-09
US20190152955A1 (en) 2019-05-23
CN104053439A (zh) 2014-09-17
ES2689481T3 (es) 2018-11-14
MX368157B (es) 2019-09-20
CA2853455A1 (en) 2013-05-02
EP3461820B1 (en) 2020-07-29
JP2014530915A (ja) 2014-11-20
IN2014DN03155A (hu) 2015-05-22
BR112014009910A2 (pt) 2017-04-25
US20180201605A1 (en) 2018-07-19
KR102087020B1 (ko) 2020-03-11
EP2776023B1 (en) 2016-03-09
ES2574262T3 (es) 2016-06-16
CY1123426T1 (el) 2021-12-31
CA2853455C (en) 2019-12-03
CN104053439B (zh) 2016-08-24
US20160340338A1 (en) 2016-11-24
ES2818977T3 (es) 2021-04-14
EP2776023A1 (en) 2014-09-17

Similar Documents

Publication Publication Date Title
HUE052128T2 (hu) Eljárás az 1-(5,6-diklór-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-karbonsav meglumin sója kristályainak elõállítására
EP2439173A4 (en) METHOD FOR PRODUCING AN IMPEDICATIVE SALT
ZA201004848B (en) Method for the production of disubstituted imidazolium salts
EP2679592A4 (en) NEW HETEROCYCLIC COMPOUND, PROCESS FOR PRODUCING INTERMEDIATE PRODUCTS THEREOF AND USE THEREOF
IL223813A0 (en) Process for preparation of optically active diamine derivative salt
IL258704B (en) History of hydantoins used as kv3 inhibitors
EP2715383A4 (en) METHOD FOR DETERMINING THE INTACTNESS OF AN ENERGY STORAGE SYSTEM
EP2755955A4 (en) METHOD FOR PRODUCING SUBSTITUTED 3'-HYDRAZIN BIPHENYL-3-CARBOXYLIC ACID COMPOUNDS
IL220211A (en) Process for Preparation of Acid History 1 - (Alkyl / Phenyl / Pyrid-2-Il) -5-Carboxylic Pyrazole and Intermediates Obtained in This Process
EP2767590A4 (en) PROCESS FOR THE PREPARATION OF 3-HYDROXY-BUTTERIC ACID OR A SALT THEREOF
HUE026564T2 (hu) Eljárás fenilszubsztituált 3-difluormetil-1-metil-1H-pirazol-4-karbonsav-N-metoxi-[1-metil-2-feniletil]-amidok elõállítására
HK1177211A1 (en) Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same
SI2635563T1 (sl) Kristaliniäśne oblike hidrokloridne soli (4a-r,9a-s)-1-(1h-benzoimidazol -5-karbonil)-2,3,4,4a,9,9a-heksahidro-1h-indeno(2,1-b)piridin-6- karbonitrila in njihove uporabe kot inhibitorji hsd
HK1168588A1 (en) Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)- cyclopropanecarboxylic acid 1-(2--4-)-
EP2436670A4 (en) PREPARATION AND USE OF 1- (SUBSTITUTED ARYL) -5-TRIFLUOROMETHYL-2- (1H) -PYRIDONE COMPOUNDS AND THEIR SALTS
EP2663646A4 (en) METHOD FOR PRODUCING NICOTIC ACID
IL207431A0 (en) New process for the preparation of cyclohexanecarboxylic acid derivatives
PL2443082T3 (pl) Sposób wytwarzania kryształów kwasu adypinowego
IL227317A0 (en) A process for the preparation of pyrazole carboxylic acid amide
EP2687515A4 (en) PROCESS FOR PREPARING A PYRAZOL CARBOXYLIC ACID DERIVATIVE
ZA201308884B (en) Production method of imidazole derivatives
IL221005A (en) Method for Synthesis of 5-Amino-1-Phenyl-3-Cyano-4-Trifluoromethyl Sulfinyl Phosphorus
IL221258A0 (en) Method for producing cyanoalkenylcyclopropanecarboxylic acid salt
IL223369A (en) METHOD FOR PRODUCING OPTICALLY ACTIVATIC COMPOSITION OF 3-MATURED ACID-3-FORMAL-2-HYDROXYPROPANOUS
ZA201207417B (en) Process for the direct preparation of malic acid salt of sunitinib